Dose-related antibody responses to purified Vero cell rabies vaccine in healthy Thai children

被引:0
|
作者
Chanthavanich, P [1 ]
Sabchareon, A [1 ]
Singhasivanon, V [1 ]
Pojjaroen-Anant, C [1 ]
Chongsuphajaisiddhi, T [1 ]
Kittikoon, P [1 ]
机构
[1] Mahidol Univ, Fac Trop Med, Dept Trop Pediat, Bangkok 10400, Thailand
来源
RABIES CONTROL IN ASIA | 1997年
关键词
PVRV; dose-related; children;
D O I
暂无
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
To study whether the response to tissue culture rabies vaccine in children is dose related, 82 children aged 7-13 years (mean: 9.5 years), weighing 17-40 kg (mean: 25 kg), were divided randomly into three groups. All of the children received purified Vero cell rabies vaccine 2-1-1 intramuscular regimen (two sites on day 0, one site each on days 7 and 21). Group I (n = 29) received a full dose of 0.5 mt (antigenic value: 7.1 international units [IU]/dose), group II (n = 26) received a half dose of 0.25 mL (antigenic value: 3.55 IU/dose), and group III (n = 27) received a one-third dose of 0.15 mL (antigenic value: 2.13 IU/dose). The rapid fluorescent focus inhibition test (RFFIT) was used to measure the neutralizing antibody (Nab). The results showed that all of the children seroconverted (> 0.5 IU/mL) on day 14. The Nab responses were dose related. The geometric mean titers (GMT) on days 14, 28, 91, and 182 of group I were 23 (range: 4-134), 18 (range: 3-86), 3 (range: 1-25), and 1 (range. < 0.5-18) IU/mL, respectively. The GMT values of group II on the corresponding days were 20 (range: 5-186), 11 (range: 3-159), 1 (range: 0.5-14), and 1 (range: < 0.5-9) IU/mL. Although the Nab levels in group II were lower than those in group I, the differences were not statistically significant. The GMT of group III on days 14 and 28, which were 6 (range: 0.5-29) and 7 (range: 1-29) IU/mL, were significantly lower than those of groups I and II (P < 0.05). However, the GMT on days 91 and 182 of group III, 1 (range: < 0.5-10) and 0.5 (range: < 0.5-7) IU/mL, were not significantly different from those of groups I and II. In conclusion, when antigenic value of rabies vaccine is less than 2.5 IU/dose (group III), the immune response is relatively poor. The doses of rabies post-exposure vaccination in children should not be reduced.
引用
收藏
页码:97 / 100
页数:4
相关论文
共 19 条
  • [1] A Comparative Study on the Adverse Reactions of Purified Chick Embryo Cell Vaccine (PCECV) and Purified Vero Cell Rabies Vaccine (PVRV)
    Ramezankhani, Roghieh
    Shirzadi, Mohammad Reza
    Ramezankhani, Azra
    Mozafary, Jamshid Poor
    ARCHIVES OF IRANIAN MEDICINE, 2016, 19 (07) : 502 - 507
  • [2] Immunogenicity and safety of inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children
    Chanthavanich, Pornthep
    Limkittikul, Kriengsak
    Sirivichayakul, Chukiat
    Chokejindachai, Watcharee
    Hattasingh, Weerawan
    Pengsaa, Krisana
    Surangsrirat, Surachai
    Srisuwannaporn, Termsang
    Kaewma, Benjawan
    Yoksan, Sutee
    Jun, Gao
    Zhumu, Bai
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018, 14 (04) : 900 - 905
  • [3] Immunogenicity and safety of WHO-approved TRC-ID regimen with a chromatographically purified Vero cell rabies vaccine with or without rabies immunoglobulin in children
    Angsuwatcharakon, Piyada
    Khomvilai, Sumana
    Limsuwun, Kornvika
    Ratananpinit, Natchaya
    Khamchat, Apinya
    Sanitnai, Teeranit
    Tantawichien, Terapong
    EXPERT REVIEW OF VACCINES, 2018, 17 (02) : 185 - 188
  • [4] Persistence of antibodies in children after intradermal or intramuscular administration of preexposure Primary and booster immunizations with purified Vero cell rabies vaccine
    Sabchareon, A
    Chantavanich, P
    Pasuralertsakul, S
    Pojjaroen-Anant, C
    Prarinyanupharb, V
    Attanath, P
    Singhasivanon, V
    Buppodom, W
    Lang, J
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1998, 17 (11) : 1001 - 1007
  • [5] Antibody persistence upto 5 years after primary immunization and booster with an inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children
    Hattasingh, Weerawan
    Chanthavanich, Pornthep
    Sirivichayakul, Chukiat
    Arunsodsai, Watcharee
    Surangsrirat, Surachai
    Srisuwannaporn, Termsang
    Kaewma, Benjawan
    Yoksan, Sutee
    Limkittikul, Kriengsak
    Yang, Junwei
    Mao, Yu
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2022, 18 (01)
  • [6] Safety and immunogenicity of chromatographically purified Vero cell rabies vaccine for intradermal pre- and post-exposure rabies prophylaxis
    Tantawichien, Terapong
    Sibunruang, Suda
    Tantawichien, Thanphet
    Angsanakul, Jaruboot
    Benjavongkulchai, Maneerat
    Limsuwan, Kornvika
    Udomchaisakul, Piyada
    Khomvilai, Sumana
    Sitprija, Visith
    EXPERT REVIEW OF VACCINES, 2014, 13 (12) : 1593 - 1601
  • [7] Safety of purified Vero cell rabies vaccine manufactured in Pakistan: a comparative analysis of intradermal and intramuscular routes
    Ali, Waqar
    Tajik, Mohammad Ismail
    Ali, Iftikhar
    Gul, Alia
    Khan, Jehan Zeb
    CURRENT MEDICAL RESEARCH AND OPINION, 2023, 39 (05) : 789 - 796
  • [8] Immunogenicity, safety and antibody persistence of a purified vero cell cultured rabies vaccine (Speeda) administered by the Zagreb regimen or Essen regimen in post-exposure subjects
    Shi, Nianmin
    Zhang, Yibin
    Zheng, Huizhen
    Zhu, Zhenggang
    Wang, Dingming
    Li, Sihai
    Li, Yuhua
    Yang, Liqing
    Zhang, Junnan
    Bai, Yunhua
    Lu, Qiang
    Zhang, Zheng
    Luo, Fengji
    Yu, Chun
    Li, Li
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2017, 13 (06) : 1338 - 1345
  • [9] Safety and immunogenicity of rabies pre- and post-exposure intradermal regimens using Abhayrab, a purified vero cell rabies vaccine (PVRV) produced in India in healthy volunteers: towards greater affordability of rabies prophylaxis
    Magpantay, Rio L.
    Bermal, Nancy
    Medina, Plebeian
    Quiambao, Beatriz P.
    ASIAN BIOMEDICINE, 2010, 4 (01) : 61 - 67
  • [10] Rabies pre-exposure vaccination of children with purified chick embryo cell vaccine (PCECV)
    Malerczyk, Claudius
    Vakil, Hoshang B.
    Bender, Wolfgang
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2013, 9 (07) : 1454 - 1459